RxDoctor Payments Data

Harwinder Singh, MD

Physical Medicine & Rehabilitation · Fresno, CANPI 1346211620

Payments from drug & device makers

$5,672in general payments, 2019–2025

Across 166 payments — averaging $34.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$560
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$429
  • AbbVie$424
  • Medtronic$377
  • Collegium Pharmaceutical, Inc.$335
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,667100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,672 in reported general payments places this provider in the 90th percentile of 830 physical medicine & rehabilitation providers in California.

See all physical medicine & rehabilitation providers in California

Medicare billing

Part B allowed, 2024
$522,935
Medicare patients
595
Services billed
7,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina14$30,430
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen653$18,084
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen444$17,282
RexultiBrexpiprazole11$15,867
Emgality PenGalcanezumab-Gnlm22$15,813
LyricaPregabalin12$12,413
MovantikNaloxegol Oxalate16$9,123
Gabapentin505$8,622
Lidocaine82$8,298
Fentanyl42$6,798
PristiqDesvenlafaxine Succinate13$5,732
Morphine Sulfate ErMorphine Sulfate217$5,609
Diclofenac Sodium65$5,598
Buprenorphine17$5,567
Pregabalin79$4,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$424$30,43014 claims
PfizerLyrica, Pristiq, Premarin$14$20,27736 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,053$15,86711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 830 physical medicine & rehabilitation providers in California.

Other physical medicine & rehabilitation in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →